PD-L1 is a significant biomarker because its expression on tumor cells and immune cells within the tumor microenvironment can predict the response to immunotherapy, specifically immune checkpoint inhibitors like pembrolizumab and nivolumab. High levels of PD-L1 expression are often associated with better responses to these therapies, making it a valuable tool for personalized cancer treatment.
